WO1997022363A3 - Improved pharmaceutical compositions - Google Patents

Improved pharmaceutical compositions Download PDF

Info

Publication number
WO1997022363A3
WO1997022363A3 PCT/GB1996/003137 GB9603137W WO9722363A3 WO 1997022363 A3 WO1997022363 A3 WO 1997022363A3 GB 9603137 W GB9603137 W GB 9603137W WO 9722363 A3 WO9722363 A3 WO 9722363A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
improved pharmaceutical
gene
delivery
improved
Prior art date
Application number
PCT/GB1996/003137
Other languages
French (fr)
Other versions
WO1997022363A2 (en
Inventor
David Robert Thatcher
Robin Ewart Offord
Keith Rose
Hubert Francois Gaertner
Original Assignee
Therexsys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therexsys Ltd filed Critical Therexsys Ltd
Priority to AU11850/97A priority Critical patent/AU705060B2/en
Priority to EP96942490A priority patent/EP0873138A2/en
Publication of WO1997022363A2 publication Critical patent/WO1997022363A2/en
Publication of WO1997022363A3 publication Critical patent/WO1997022363A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is based on the discovery of a gene delivery vehicle for delivery of a therapeutic gene to cells or tissues bearing the insulin receptor.
PCT/GB1996/003137 1995-12-19 1996-12-19 Improved pharmaceutical compositions WO1997022363A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU11850/97A AU705060B2 (en) 1995-12-19 1996-12-19 Improved pharmaceutical compositions
EP96942490A EP0873138A2 (en) 1995-12-19 1996-12-19 Improved pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9525955.2A GB9525955D0 (en) 1995-12-19 1995-12-19 Improved pharmaceutical compositions
GB9525955.2 1995-12-19

Publications (2)

Publication Number Publication Date
WO1997022363A2 WO1997022363A2 (en) 1997-06-26
WO1997022363A3 true WO1997022363A3 (en) 1997-09-25

Family

ID=10785695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003137 WO1997022363A2 (en) 1995-12-19 1996-12-19 Improved pharmaceutical compositions

Country Status (5)

Country Link
EP (1) EP0873138A2 (en)
AU (1) AU705060B2 (en)
CA (1) CA2241040A1 (en)
GB (1) GB9525955D0 (en)
WO (1) WO1997022363A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002135A1 (en) * 1988-08-26 1990-03-08 Robin Ewart Offord Protein derivatives and a process for their preparation
EP0359428A1 (en) * 1988-08-26 1990-03-21 Robin Ewart Offord Protein derivatives and a process for their preparation
WO1996041813A2 (en) * 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002135A1 (en) * 1988-08-26 1990-03-08 Robin Ewart Offord Protein derivatives and a process for their preparation
EP0359428A1 (en) * 1988-08-26 1990-03-21 Robin Ewart Offord Protein derivatives and a process for their preparation
WO1996041813A2 (en) * 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.A. ROSENKRANTZ ET AL.: "RECEPTOR-MEDIATED ENDOCYTOSIS AND NUCLEAR TRANSPORT OF A TRANSFECTING DNA CONSTRUCT.", EXPERIM. CELL RESEARCH, vol. 199, no. 2, 1992, pages 323 - 329, XP002036700 *
ROSE, KEITH ET AL: "Attachment of linker groups to carboxyl termini using enzyme-assisted reverse proteolysis", PEPT., PROC. EUR. PEPT. SYMP., 20TH (1989), MEETING DATE 1988, 274-6. EDITOR(S): JUNG, GUENTHER;BAYER, ERNST. PUBLISHER: DE GRUYTER, BERLIN, FED. REP. GER. CODEN: 57ACAI, 1989, XP002036701 *
VILASECA L ET AL: "PROTEIN CONJUGATES OF DEFINED STRUCTURE: SYNTHESIS AND USE OF A NEW CARRIER MOLECULE", BIOCONJUGATE CHEMISTRY, vol. 4, no. 6, 1 November 1993 (1993-11-01), pages 515 - 520, XP000417288 *

Also Published As

Publication number Publication date
AU1185097A (en) 1997-07-14
WO1997022363A2 (en) 1997-06-26
EP0873138A2 (en) 1998-10-28
CA2241040A1 (en) 1997-06-26
AU705060B2 (en) 1999-05-13
GB9525955D0 (en) 1996-02-21

Similar Documents

Publication Publication Date Title
AU9224498A (en) Matrix for controlled delivery of highly soluble drugs
AU6011496A (en) Improved pharmaceutical compositions for gene therapy
AU6075198A (en) Drug delivery system for two or more active substances
AU6958996A (en) Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU5869796A (en) Micromechanical patch for enhancing the delivery of compound s through the skin
AU4835396A (en) Composition containing nucleic acids, preparation and use
AU5402296A (en) Pharmaceutical composition for transdermic administration
AU5945296A (en) Medicament for nasal administration
AU1175000A (en) Local delivery of drugs to the colon for local treatment of colonic diseases
AU1529397A (en) Delivery system for localized administration of medicaments to the upper respiratory tract
AU6527596A (en) Lipid vehicle drug delivery composition containing vitamin e
AU7123296A (en) Liposomal formulations of mitoxantrone
AU5945396A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
IL112372A0 (en) Non-viral vector
AU7117196A (en) Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
CA2329005A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
AU2053597A (en) Pharmaceutical compositions for the treatment of glaucoma
AU2845599A (en) Pharmaceutical compositions and their use
MX9605023A (en) Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
AU1061699A (en) Use of biologically active glass as a drug delivery system
CA2294783A1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
CA2270177A1 (en) Transdermal administration of ment
AU7294196A (en) Stable pharmaceutical forms of administration containing parathormone
EP1978031A3 (en) Tropoelastin derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

ENP Entry into the national phase

Ref document number: 2241040

Country of ref document: CA

Ref country code: CA

Ref document number: 2241040

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996942490

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97522587

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996942490

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996942490

Country of ref document: EP